Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have earned an average recommendation of “Moderate Buy” from the three brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $5.08.

MCRB has been the subject of several research analyst reports. JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday. Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 target price on shares of Seres Therapeutics in a report on Friday, September 13th. Chardan Capital reaffirmed a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a research note on Wednesday, August 14th. Finally, StockNews.com cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 13th.

Seres Therapeutics Stock Performance

MCRB opened at $0.76 on Thursday. The stock has a market capitalization of $114.65 million, a price-to-earnings ratio of -1.26 and a beta of 2.03. The company has a fifty day moving average of $0.90 and a 200 day moving average of $0.91. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $2.05.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. During the same period in the previous year, the business posted $0.36 EPS. On average, equities research analysts forecast that Seres Therapeutics will post -0.95 earnings per share for the current year.

Insider Activity at Seres Therapeutics

In other Seres Therapeutics news, insider Teresa L. Young sold 24,480 shares of Seres Therapeutics stock in a transaction on Monday, August 5th. The shares were sold at an average price of $1.08, for a total transaction of $26,438.40. Following the completion of the transaction, the insider now directly owns 78,178 shares of the company’s stock, valued at $84,432.24. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 28,844 shares of company stock worth $30,104. Company insiders own 5.10% of the company’s stock.

Institutional Trading of Seres Therapeutics

Several institutional investors have recently added to or reduced their stakes in MCRB. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Seres Therapeutics in the first quarter worth approximately $39,000. Providence Wealth Advisors LLC grew its position in Seres Therapeutics by 49.5% in the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 25,250 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in Seres Therapeutics in the second quarter worth $64,000. Virtu Financial LLC bought a new stake in shares of Seres Therapeutics during the first quarter worth $73,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Seres Therapeutics during the second quarter valued at $92,000. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.